US Patent
US11389448 — Freeze dried drug nanosuspensions
Formulation · Assigned to Janssen Pharmaceutica NV · Expires 2032-04-13 · 6y remaining
Vulnerability score
61/100
Moderate — design-around opportunities exist
What this patent protects
This patent protects a freeze-dried drug nanosuspension composition with stable particle size distribution during storage.
USPTO Abstract
The present invention relates to a freeze-dried (also called lyophilized) drug nanosuspension. The present freeze-dried drug nanosuspension composition has an acceptable stability of the particle size distribution during storage, including long term storage.
Drugs covered by this patent
- Vocabria (CABOTEGRAVIR) · GSK
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.